GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » PELL Bio-Med Technology Co Ltd (TPE:6949) » Definitions » Notes Receivable

PELL Bio-Med Technology Co (TPE:6949) Notes Receivable : NT$0.00 Mil (As of Mar. 2025)


View and export this data going back to 2024. Start your Free Trial

What is PELL Bio-Med Technology Co Notes Receivable?

PELL Bio-Med Technology Co's Notes Receivable for the quarter that ended in Mar. 2025 was NT$0.00 Mil.


PELL Bio-Med Technology Co Notes Receivable Historical Data

The historical data trend for PELL Bio-Med Technology Co's Notes Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

PELL Bio-Med Technology Co Notes Receivable Chart

PELL Bio-Med Technology Co Annual Data
Trend Dec21 Dec22 Dec23 Dec24
Notes Receivable
- - - -

PELL Bio-Med Technology Co Quarterly Data
Dec21 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Notes Receivable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

PELL Bio-Med Technology Co Notes Receivable Calculation

Notes Receivable is an unconditional promise to receive a definite sum of money at a future date(s) within one year of the balance sheet date or the normal operating cycle, whichever is longer.


PELL Bio-Med Technology Co Notes Receivable Related Terms

Thank you for viewing the detailed overview of PELL Bio-Med Technology Co's Notes Receivable provided by GuruFocus.com. Please click on the following links to see related term pages.


PELL Bio-Med Technology Co Business Description

Traded in Other Exchanges
N/A
Address
No. 87, Xinhu 2nd Road, 4th Floor, Neihu District, Taipei, TWN
PELL Bio-Med Technology Co Ltd is a company engaged in the research and development and application of autologous T Cell Therapy (Adoptive T Cell Therapy), CAR-T (Chimeric Antigen Receptor T cell), and Gene-Modified Adipose-Derived Stem Cell (Gene-Modified Adipose-Derived Stem Cell).

PELL Bio-Med Technology Co Headlines

No Headlines